Quotes 5-day view Delayed Nyse
03/01/2021
03/02/2021
03/03/2021
03/04/2021
03/05/2021
Date
206.47(c)
204.14(c)
202(c)
200.54(c)
206.92(c)
Last
2 797 548
3 445 286
3 660 317
4 308 430
3 805 681
Volume
+0.77% -1.13% -1.05% -0.72% +3.18% Change
Sales 2021
27 838 M - -
Net income 2021
7 091 M - -
Net Debt 2021
9 688 M - -
P/E ratio 2021
26,6x
Yield 2021
1,64%
Sales 2022
28 067 M - -
Net income 2022
7 583 M - -
Net Debt 2022
6 771 M - -
P/E ratio 2022
24,4x
Yield 2022
1,80%
Capitalization
188 B 188 B -
EV / Sales 2021
7,10x
EV / Sales 2022
6,94x
Nbr of Employees
35 000
Free-Float
99,6%
Eli Lilly and Company is a drug manufacturing company. The Company discover, develop, manufacture, and market products in a human pharmaceutical product segment. The Company’s products include Diabetes and other endocrinology products, including Baqsimi, Basaglar, Forteo, Humalog, Humatrope, Humulin, Jardiance, Trajenta and Trulicity. Its Immunology products include Olumiant and Taltz. Its Neuroscience products...
Notations Surperformance© of Eli Lilly and Company
Trading Rating : Investor Rating :
All news about ELI LILLY AND COMPANY
News in other languages on ELI LILLY AND COMPANY
Analyst Recommendations on ELI LILLY AND COMPANY
Lilly says CFO resigns after investigation into inappropriate relationship
Chart ELI LILLY AND COMPANY
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends ELI LILLY AND COMPANY
Short Term Mid-Term Long Term Trends Neutral Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
22
Average target price
210,65 $
Last Close Price
206,92 $
Spread / Highest target
23,7%
Spread / Average Target
1,80%
Spread / Lowest Target
-42,0%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
